https://amr-accelerator.eu/wp-content/uploads/2023/02/tb-icon.png200200Tolga/wp-content/uploads/2024/08/IMI-AMR-Accelerator_Slogan_quer_RGB.pngTolga2023-01-18 11:02:032023-09-05 15:37:16RespiriNTM – Specificity of the innate immune responses to different classes of non-tuberculous mycobacteria
https://amr-accelerator.eu/wp-content/uploads/2023/02/tb-icon.png200200Tolga/wp-content/uploads/2024/08/IMI-AMR-Accelerator_Slogan_quer_RGB.pngTolga2022-12-01 14:20:142023-05-12 14:24:01UNITE4TB – Implementing molecular tuberculosis diagnostic methods in limited-resource and high-burden countries
https://amr-accelerator.eu/wp-content/uploads/2023/02/tb-icon.png200200Tolga/wp-content/uploads/2024/08/IMI-AMR-Accelerator_Slogan_quer_RGB.pngTolga2022-11-15 14:56:322023-05-12 14:57:43ERA4TB – Microfluidic dose–response platform to track the dynamics of drug response in single mycobacterial cells
https://amr-accelerator.eu/wp-content/uploads/2023/02/capability-icon.png200200Tolga/wp-content/uploads/2024/08/IMI-AMR-Accelerator_Slogan_quer_RGB.pngTolga2022-10-13 15:31:362023-05-12 15:31:48PrIMAVeRa – Estimating antimicrobial resistance burden in Europe: what are the next steps?
https://amr-accelerator.eu/wp-content/uploads/2023/02/gram-neg-icon.png200200Tolga/wp-content/uploads/2024/08/IMI-AMR-Accelerator_Slogan_quer_RGB.pngTolga2022-10-06 15:04:432023-05-12 15:12:40GNA NOW – Exploring Cluster-Dependent Antibacterial Activities and Resistance Pathways of NOSO-502 and Colistin against Enterobacter cloacae Complex Species
https://amr-accelerator.eu/wp-content/uploads/2023/02/capability-icon.png200200u.mommert/wp-content/uploads/2024/08/IMI-AMR-Accelerator_Slogan_quer_RGB.pngu.mommert2022-09-08 14:20:452023-05-12 11:35:32COMBINE – Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents
https://amr-accelerator.eu/wp-content/uploads/2023/02/tb-icon.png200200u.mommert/wp-content/uploads/2024/08/IMI-AMR-Accelerator_Slogan_quer_RGB.pngu.mommert2022-07-22 21:29:052023-05-12 14:27:00UNITE4TB – Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin
https://amr-accelerator.eu/wp-content/uploads/2023/02/tb-icon.png200200Tolga/wp-content/uploads/2024/08/IMI-AMR-Accelerator_Slogan_quer_RGB.pngTolga2022-03-21 14:30:132023-07-17 14:39:34UNITE4TB – Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies
We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Google Webfont Settings:
Vimeo and Youtube video embeds:
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, you cannot refuse them without impacting how our site functions. You can block or delete them by changing your browser settings and force blocking all cookies on this website.
Other external services
We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Vimeo and Youtube video embeds:
Privacy Policy
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
